Arcellx Inc (ACLX) Stock Price, Quote & News

Company Profile

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 327 0630

Website: www.arcellx.com

Address:

800 Bridge Parkway, Redwood City, United States

Iightning Dec. 4 at 9:24 PM

1ightning® Premium Options Alert (Actionable) Ticker: $ACLX Contract: Dec 19 $70C Entry: 4.25 Exit: 5.21 Return: +22.66% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

options1315 Dec. 4 at 7:55 PM

$ACLX I absolutely NAILED this SHORT.

0 · Reply

MoneyGroupLLC Dec. 4 at 6:11 PM

Enter: $ACLX Calls Strike Price: $80 Expiry Date: JAN 16 2026 Buy in Price: $4.30 - $4.90 Sell Price: $6.45 Profit : +50% (Turn every $1 into $1.50) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Iightning Dec. 4 at 5:05 AM

1ightning® Premium Options Alert (Actionable) Ticker: $ACLX Contract: Dec 19 $75C Entry: 2.90 Exit: 4.77 Return: +64.59% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

justiceforb_85 Dec. 4 at 2:16 AM

$ACLX think we'll see a positive update over the weekend.

0 · Reply

options1315 Dec. 3 at 8:33 PM

$ACLX texbook dead cat bounce. Great time to sell.

1 · Reply

MoneyGroupLLC Dec. 3 at 11:21 AM

Enter: $ACLX Calls Strike Price: $80 Expiry Date: JAN 16 2026 Buy in Price: $4.30 - $4.51 Sell Price: $7.57 Profit : +76% (Turn every $1 into $1.76) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Iightning Dec. 3 at 9:18 AM

1ightning® Premium Options Alert (Actionable) Ticker: $ACLX Contract: Dec 19 $50C Entry: 40.25 Exit: 60.37 Return: +49.99% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 1 at 11:18 PM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $ACLX **Contract:** Dec 19 $75C **Entry:** 3.35 **Exit:** 5.27 **Return:** **+57.19% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

MoneyGroupLLC Nov. 29 at 11:35 AM

Enter: $ACLX Calls Strike Price: $75 Expiry Date: DEC 19 2025 Buy in Price: $4.10 - $4.30 Sell Price: $7.09 Profit : +73% (Turn every $1 into $1.73) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition

Nov 5, 2025, 4:00 PM EST - 4 weeks ago

Arcellx Provides Third Quarter 2025 Financial Results

Nov 3, 2025, 9:00 AM EST - 4 weeks ago

Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition

Sep 10, 2025, 3:50 PM EDT - 3 months ago

Arcellx, Inc. (ACLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 3, 2025, 4:00 PM EDT - 3 months ago

Arcellx to Participate at the 2025 Morgan Stanley Global Healthcare Conference

Aug 7, 2025, 9:45 PM EDT - 4 months ago

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

BSX EW EXAS GH ISRG LLY MASI

Aug 7, 2025, 4:53 PM EDT - 4 months ago

Arcellx (ACLX) Q2 Revenue Drops 72%

Aug 7, 2025, 4:00 PM EDT - 4 months ago

Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights

Jul 15, 2025, 4:51 PM EDT - 5 months ago

Arcellx: Anito-Cel With D-Domain Differentiation Looks To Capture R/R MM Market

May 21, 2025, 4:00 PM EDT - 7 months ago

Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

$Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma$

May 14, 2025, 9:30 AM EDT - 7 months ago

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

May 8, 2025, 4:00 PM EDT - 7 months ago

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

Apr 29, 2025, 11:45 AM EDT - 7 months ago

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

ISRG MASI MCK NTRA PEN TMO UNH

Apr 29, 2025, 11:30 AM EDT - 7 months ago

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

BSX DHR GKOS INSM ISRG LLY RDNT

Mar 20, 2025, 4:00 PM EDT - 9 months ago

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

Mar 18, 2025, 8:44 AM EDT - 9 months ago

Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month

Mar 17, 2025, 11:27 AM EDT - 9 months ago

Arcellx Impressive Safety Data Leaves Doubts

Feb 27, 2025, 4:00 PM EST - 10 months ago

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

Feb 26, 2025, 4:00 PM EST - 10 months ago

Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference

Dec 9, 2024, 7:50 AM EST - 1 year ago

Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients

$Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition$

Dec 8, 2024, 11:00 PM EST - 1 year ago

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

Nov 7, 2024, 4:00 PM EST - 1 year ago

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

$Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study$

Nov 5, 2024, 9:00 AM EST - 1 year ago

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

Sep 10, 2024, 8:30 AM EDT - 1 year ago

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

Aug 8, 2024, 4:00 PM EDT - 1 year ago

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates

Jun 26, 2024, 11:19 AM EDT - 1 year ago

Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market

May 9, 2024, 4:05 PM EDT - 1 year ago

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

GILD

May 9, 2024, 4:05 PM EDT - 1 year ago

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

GILD

May 9, 2024, 4:00 PM EDT - 1 year ago

Arcellx Provides First Quarter 2024 Financial Results

May 7, 2024, 4:00 PM EDT - 1 year ago

Arcellx to Participate in Two Upcoming Investor Conferences

Apr 4, 2024, 4:00 PM EDT - 1 year ago

Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 20, 2024, 4:00 PM EDT - 1 year ago

Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Feb 29, 2024, 4:00 PM EST - 1 year ago

Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference

Feb 28, 2024, 4:00 PM EST - 1 year ago

Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights

Jan 30, 2024, 5:13 AM EST - 2 years ago

Arcellx: Navigating The CAR T-Cell Revolution

$Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH$

Dec 8, 2023, 4:00 PM EST - 2 years ago

Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH

Nov 15, 2023, 1:44 PM EST - 2 years ago

Arcellx: A Strong Contender In The CAR-T Multiple Myeloma Market

Nov 15, 2023, 6:23 AM EST - 2 years ago

Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premium

GILD

Nov 15, 2023, 6:00 AM EST - 2 years ago

Kite and Arcellx Announce Expansion in Strategic Partnership

GILD

Nov 15, 2023, 6:00 AM EST - 2 years ago

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

GILD

Nov 13, 2023, 4:00 PM EST - 2 years ago

Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights

$Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition$

Nov 2, 2023, 9:00 AM EDT - 2 years ago

Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition

Aug 14, 2023, 4:00 PM EDT - 2 years ago

Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results

Jun 19, 2023, 7:46 PM EDT - 2 years ago

Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program

May 8, 2023, 4:00 PM EDT - 2 years ago

Arcellx Provides First Quarter Financial Results

Apr 13, 2023, 4:01 PM EDT - 2 years ago

Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference

Mar 29, 2023, 4:01 PM EDT - 2 years ago

Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights

Feb 21, 2023, 4:00 PM EST - 3 years ago

Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference

Feb 2, 2023, 4:00 PM EST - 3 years ago

Arcellx to Participate in Upcoming Investor Conferences

Iightning Dec. 4 at 9:24 PM

1ightning® Premium Options Alert (Actionable) Ticker: $ACLX Contract: Dec 19 $70C Entry: 4.25 Exit: 5.21 Return: +22.66% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

options1315 Dec. 4 at 7:55 PM

$ACLX I absolutely NAILED this SHORT.

0 · Reply

MoneyGroupLLC Dec. 4 at 6:11 PM

0 · Reply

Iightning Dec. 4 at 5:05 AM

1ightning® Premium Options Alert (Actionable) Ticker: $ACLX Contract: Dec 19 $75C Entry: 2.90 Exit: 4.77 Return: +64.59% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

justiceforb_85 Dec. 4 at 2:16 AM

$ACLX think we'll see a positive update over the weekend.

0 · Reply

options1315 Dec. 3 at 8:33 PM

$ACLX texbook dead cat bounce. Great time to sell.

1 · Reply

MoneyGroupLLC Dec. 3 at 11:21 AM

0 · Reply

Iightning Dec. 3 at 9:18 AM

1ightning® Premium Options Alert (Actionable) Ticker: $ACLX Contract: Dec 19 $50C Entry: 40.25 Exit: 60.37 Return: +49.99% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 1 at 11:18 PM

0 · Reply

MoneyGroupLLC Nov. 29 at 11:35 AM

0 · Reply

MoneyGroupLLC Nov. 27 at 11:30 AM

Enter: $ACLX Calls Strike Price: $75 Expiry Date: DEC 19 2025 Buy in Price: $4.53 - $4.76 Sell Price: $10.10 Profit : +123% (Turn every $1 into $2.23) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

Iightning Nov. 26 at 2:07 AM

1ightning® Options Trade Alert (Actionable) | Buy $ACLX Dec 19 $75 Call | Enter: $5.86 Exit: $10.80 | Profit: 84.33% ROI | https://1ightning.com

0 · Reply

MoneyGroupLLC Nov. 26 at 1:50 AM

Enter: $ACLX Calls Strike Price: $75 Expiry Date: DEC 19 2025 Buy in Price: $5.57 - $7.60 Sell Price: $7.91 Profit : +42% (Turn every $1 into $1.42) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

wushbet Nov. 25 at 2:23 PM

$ACLX this is in 2023. What is your points

0 · Reply

Iightning Nov. 25 at 12:12 PM

1ightning® Options Trade Alert (Actionable) | Buy $ACLX Dec 19 $75 Call | Enter: $5.86 Exit: $10.80 | Profit: 84.33% ROI | https://1ightning.com

0 · Reply

Arcides Nov. 25 at 1:31 AM

$ACLX the highest volume in a year, not grandma selling

0 · Reply

Iightning Nov. 25 at 1:08 AM

1ightning® Options Trade Alert (Actionable) | Buy $ACLX Dec 19 $75 Call | Enter: $5.86 Exit: $10.80 | Profit: 84.33% ROI | https://1ightning.com

0 · Reply

AStrokeOfLuck Nov. 25 at 12:26 AM

$ACLX

0 · Reply

UnoffensiveName Nov. 24 at 11:50 PM

$ACLX buying at 69 please

0 · Reply

lebranjames Nov. 24 at 11:26 PM

$ACLX 1 year of gains washed out in a day

0 · Reply

wushbet Nov. 24 at 9:29 PM

$ACLX it was up with 3 patient only and should go down with 3 patient. Welcome to pharma

0 · Reply

lonelywarrior Nov. 24 at 9:08 PM

$ACLX Phase 1 data for 3 patients only - that nonsense is beyond anecdotal. This selloff is not grounded in reality.

0 · Reply

Market Cap	3.98B
Revenue (ttm)	107.94M
Net Income (ttm)	-107.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-99.45%
Debt to Equity Ratio	0.00

Volume	2,207,379
Avg Vol	705,188
Day's Range	N/A - N/A
Shares Out	57.82M
Stochastic %K	19%
Beta	0.34
Analysts	Strong Sell
Price Target	$114.81